Editas Medicine (EDIT) Stock Price, Quote & News

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

Whoami1989 Feb. 6 at 3:02 PM

$EDIT another day where idiotic day traders sell to profit few pennies

0 · Reply

Erminiottone Feb. 6 at 2:51 PM

$EDIT Another beautiful red day. Absolute no-brainer. This thing is a fat pig begging to be shorted all the way down to pennyland. Thank you, gentlemen.

0 · Reply

StockBraker Feb. 6 at 12:33 PM

$EDIT Some people (me) just can't learn a lesson except the hard way. 😉🤣

0 · Reply

Robert_Dempster Feb. 5 at 9:05 PM

$EDIT great opportunity to load🎯🐂🐂

1 · Reply

DoctrBenway Feb. 5 at 9:02 PM

$EDIT Added 3% more at 1.66. Heckofaday.

1 · Reply

Whoami1989 Feb. 5 at 9:01 PM

$EDIT fucking 15% in a day. true loser

0 · Reply

Whoami1989 Feb. 5 at 8:53 PM

$EDIT tomorrow is another day for fucking loser. fire all dumb ass scientists who collects money and produce zero result

0 · Reply

Whoami1989 Feb. 5 at 8:51 PM

$EDIT perhaps the biggest loser today and history of stock

0 · Reply

Whoami1989 Feb. 5 at 8:45 PM

$EDIT forever loser

0 · Reply

Whoami1989 Feb. 5 at 8:45 PM

$EDIT idiotic pumpers - are you buying? you better fucking but it. i need your help

0 · Reply

Genflow Biosciences PLC Announces Directorate Change

Nov 10, 2025, 7:00 AM EST - 3 months ago

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Nov 3, 2025, 9:00 AM EST - 3 months ago

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Oct 14, 2025, 6:18 PM EDT - 4 months ago

Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm?

Oct 9, 2025, 11:01 AM EDT - 4 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Oct 6, 2025, 9:00 AM EDT - 4 months ago

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Sep 2, 2025, 11:14 AM EDT - 5 months ago

Editas Medicine, Inc. - Special Call

Sep 2, 2025, 7:00 AM EDT - 5 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Aug 28, 2025, 4:01 PM EDT - 5 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

Aug 27, 2025, 9:00 AM EDT - 5 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Aug 12, 2025, 4:01 PM EDT - 6 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Jun 12, 2025, 2:01 AM EDT - 8 months ago

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 20, 2025, 5:47 AM EDT - 9 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

May 14, 2025, 2:17 PM EDT - 9 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 9:31 AM EDT - 9 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 9 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 9 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 9 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 9 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 9 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 10 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 11 months ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 4:07 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 5, 2025, 4:05 PM EST - 1 year ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 5:01 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Feb 24, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 17, 2025, 12:20 PM EST - 1 year ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 1 year ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 1 year ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 1 year ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 1 year ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 1 year ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 1 year ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 1 year ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 4, 2024, 7:30 AM EST - 1 year ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 1 year ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 1 year ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 1 year ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 1 year ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 1 year ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 7:53 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Sep 25, 2024, 11:46 AM EDT - 1 year ago

Editas Medicine: A Risk/Reward Worth Considering

Sep 17, 2024, 5:26 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Sep 5, 2024, 11:19 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Sep 4, 2024, 7:17 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Whoami1989 Feb. 6 at 3:02 PM

$EDIT another day where idiotic day traders sell to profit few pennies

0 · Reply

Erminiottone Feb. 6 at 2:51 PM

$EDIT Another beautiful red day. Absolute no-brainer. This thing is a fat pig begging to be shorted all the way down to pennyland. Thank you, gentlemen.

0 · Reply

StockBraker Feb. 6 at 12:33 PM

$EDIT Some people (me) just can't learn a lesson except the hard way. 😉🤣

0 · Reply

Robert_Dempster Feb. 5 at 9:05 PM

$EDIT great opportunity to load🎯🐂🐂

1 · Reply

DoctrBenway Feb. 5 at 9:02 PM

$EDIT Added 3% more at 1.66. Heckofaday.

1 · Reply

Whoami1989 Feb. 5 at 9:01 PM

$EDIT fucking 15% in a day. true loser

0 · Reply

Whoami1989 Feb. 5 at 8:53 PM

$EDIT tomorrow is another day for fucking loser. fire all dumb ass scientists who collects money and produce zero result

0 · Reply

Whoami1989 Feb. 5 at 8:51 PM

$EDIT perhaps the biggest loser today and history of stock

0 · Reply

Whoami1989 Feb. 5 at 8:45 PM

$EDIT forever loser

0 · Reply

Whoami1989 Feb. 5 at 8:45 PM

$EDIT idiotic pumpers - are you buying? you better fucking but it. i need your help

0 · Reply

Whoami1989 Feb. 5 at 8:10 PM

$EDIT dear idiots - please pump this fpos up

0 · Reply

Whoami1989 Feb. 5 at 8:04 PM

$EDIT omg this fpos is over

0 · Reply

alexx013 Feb. 5 at 6:57 PM

$EDIT added @ 1.74

0 · Reply

Whoami1989 Feb. 5 at 6:52 PM

$EDIT common pumpers - lets pump it up. i am so disappointed in you. make it happen

0 · Reply

Whoami1989 Feb. 5 at 6:31 PM

$EDIT If you want your hard earned money bleeding daily, this fpos is for you

0 · Reply

Whoami1989 Feb. 5 at 6:00 PM

$EDIT just beautiful 10% haircut. few months ago was $4.5. this is either a great setup or scam

0 · Reply

Whoami1989 Feb. 5 at 5:23 PM

$EDIT if you try to pump this fpos up, then i need to see it up not down. so what the f are you doing pumpers

0 · Reply

StockBraker Feb. 5 at 5:09 PM

$EDIT Looking to add at $1.75 or less.

0 · Reply

HarryScrotmmm Feb. 5 at 3:54 PM

$EDIT I came here just to see Whoami's posts LOL

2 · Reply

DocPharm Feb. 5 at 3:45 PM

$EDIT probably will do some financing so they can move into human trials Either that or they will partner. Either way, buying more. If they finance, it’ll be much more

2 · Reply

DocPharm Feb. 5 at 3:42 PM

$XBI wants to fill 123.25 before going back up $ROIV $ABUS $ALT $EDIT

1 · Reply

alexx013 Feb. 5 at 3:25 PM

$EDIT bought more @1.82

0 · Reply

Market Cap	190.36M
Revenue (ttm)	32.31M
Net Income (ttm)	-237.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-733.80%
Debt to Equity Ratio	0.00

Volume	1,221,558
Avg Vol	1,772,750
Day's Range	N/A - N/A
Shares Out	97.62M
Stochastic %K	1%
Beta	2.15
Analysts	Sell
Price Target	$4.91